Antiquus illness
A team of scientists has produced evidence that the pathogen, Mycobacterium tuberculosis, was present over 17000 years ago in a skeleton of extinct Bison antiquus.
A team of scientists has produced evidence that the pathogen, Mycobacterium tuberculosis, was present over 17 000 years ago in a skeleton of extinct Bison antiquus.1 The study followed a DNA report that was performed 10 years ago and suggested that the skeleton was the oldest known case of tuberculosis.
In the most recent study the team used fluorescence high-performance liquid chromatography (HPLC) on the same two samples from the bison. They were able to indicate the presence of mycolic acids but they were degraded and could not be precisely correlated with tuberculosis. However, C29, C30 and C32 mycocerosates and C27 mycolipenates, which are typical of the Mycobacterium tuberculosis complex, were recorded when negative ion chemical ionization gas chromatography mass spectrometry (NICI-GC–MS) was used. These findings were supported by the detection of C34 and C36 phthiocerols, which are usually esterified to the mycocerosates.
The team deduced that they had found conclusive evidence for the presence of tuberculosis in the bison samples. They also concluded that tuberculosis could now potentially be identified in the absence of obvious bone lesions. Of particular interest is that there is not a proven human tuberculosis sample older than 9,000 BP (Before Present), which suggests that the disease may have originated in animals before moving across to humans. More work needs to be undertaken before this hypothesis can be supported or disproved.
1. O.Y-C Lee et al., PLoS One 7(7): e41923 (2012).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
